1985
Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate
Trigg M, Makuch R, Glaubiger D. Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. International Journal Of Radiation Oncology • Biology • Physics 1985, 11: 699-702. PMID: 3838542, DOI: 10.1016/0360-3016(85)90300-1.Peer-Reviewed Original ResearchConceptsEwing's sarcomaIntrathecal methotrexateCNS irradiationProphylactic cranial irradiationGroup of patientsCurrent treatment regimensLack of efficacyNational Cancer InstituteCranial irradiationInitial therapyCNS involvementCNS recurrenceTreatment regimensCNS treatmentIrradiation regimenCancer InstituteActuarial riskSarcomaOverall riskPatientsTherapyMethotrexateRiskCNSInvolvement
1981
Influence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
1979
Recommendations for the analysis of the effect of treatment on the development of second malignancies
Makuch R, Simon R. Recommendations for the analysis of the effect of treatment on the development of second malignancies. Cancer 1979, 44: 250-253. PMID: 455251, DOI: 10.1002/1097-0142(197907)44:1<250::aid-cncr2820440141>3.0.co;2-1.Peer-Reviewed Original Research